No Data
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $Xeris Pharmaceuticals(XERS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of
Xeris Pharmaceuticals (XERS) Gets a Buy From Craig-Hallum
Xeris Pharmaceuticals Undergoes Executive Leadership Transition
Xeris Biopharma CEO Paul Edick to Retire
Express News | Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M
Xeris Biopharma Says Q2 Rev Seen Exceeding $47M, Representing More Than 23% Growth Over Last Year >XERS
Xeris Biopharma Says Q2 Rev Seen Exceeding $47M, Representing More Than 23% Growth Over Last Year >XERS